O T C
PURA Addresses Next Steps To Issue Dividend Of PAOG Stock

Dallas, TX – October 23, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today announced that PURA management and PAO Group, Inc. (PAOG) management have scheduled combined efforts next week to complete the joint documentation and submission requirements necessary to execute the planned dividend of PAOG stock to PURA shareholders.  A joint

PAOG Signs Clinical Research Organization (CRO) To Advance Respiratory Cannabis Treatment Through Regulatory Approval

Sandusky, OH – October 23, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG signed the agreement yesterday,

PURA Corporate Update To Include Latest On PAOG Dividend Scheduled For Tomorrow

Dallas, TX – October 22, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today confirmed a comprehensive corporate update scheduled for tomorrow, Friday, October 23, 2020, to provide the latest information on progress with the new Farmersville Brand strategy.  The update was coordinated to follow yesterday’s announcement of the contract to acquire

PAOG Advances FDA Application Process For Respiratory Cannabis Drug Treatment

Sandusky, OH – October 20, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG announced last week

PAOG Releases Cannabis Drug Development Update

Sandusky, OH – October 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a progress update on the company’s ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG anticipates entering into an agreement with a contract research organization (CRO) within

Contact Us

  • 707-OTC-WIRE (707-682-9473)
  • cs@otcprwire.com

All Rights Reserved © 2019